GlassScriptPhysician profile
Ryan M Carbaugh
NPI 1437541570
$9,665.28
in general payments reported to CMS, 2019-2025
38 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $1,363 · 2021: $1,366 · 2022: $1,211 · 2023: $1,232 · 2024: $1,896 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Travel and Lodging: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.67 |
| Travel and Lodging | $543.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,517.39 | 2019-2025 | Linzess, Creon, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,029.39 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Boston Scientific Corporation | $978.71 | 2019-2025 | General - Therapies, Apollo Esg Nxt System, Bodyguardian |
| Takeda Pharmaceuticals U.S.A., INC. | $801.84 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $430.28 | 2021-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $261.28 | 2019-2024 | Linzess |
| Pfizer INC. | $240.34 | 2019-2021 | |
| Genzyme Corporation | $216.08 | 2022-2025 | |
| Daiichi Sankyo INC. | $213.82 | 2019-2021 | |
| Novo Nordisk INC | $195.95 | 2019-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $152.12 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $150.28 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $144.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $123.84 | 2020-2021 | |
| Lilly USA, LLC | $99.47 | 2024-2025 | Omvoh, Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $89.17 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $86.85 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $77.53 | 2022-2023 | |
| Eisai INC. | $71.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.37 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $68.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $62.50 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $61.48 | 2020-2021 | |
| Redhill Biopharma INC. | $57.95 | 2020-2021 | |
| Qol Medical, LLC | $57.75 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $51.66 | 2023 | Zerbaxa, Dificid |
| Braintree Laboratories, INC. | $45.00 | 2019-2021 | |
| Shire North American Group INC | $44.69 | 2019 | |
| Ucb, INC. | $43.34 | 2019-2020 | |
| Celgene Corporation | $39.66 | 2021-2022 | |
| Ardelyx, INC. | $34.21 | 2023-2024 | Ibsrela |
| Glaxosmithkline, LLC. | $32.56 | 2021-2023 | Nucala |
| Grifols USA, LLC | $28.04 | 2021-2022 | |
| Concordia Pharmaceuticals INC. | $22.47 | 2019 | |
| Axsome Therapeutics, INC. | $22.22 | 2023 | Sunosi |
| Vivus LLC | $17.51 | 2021 | |
| Aimmune Therapeutics, INC. | $13.78 | 2025 | Zenpep |
| Shionogi INC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Carbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.